New perspectives on parathyroid hormone therapy

Current Opinion in Rheumatology

Volumn 17, Issue 4, 2005, Pages 467-474

  Lane, Nancy ^a   Morris, Stephen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NPS Pharmaceutical Inc   (United States)

Author keywords

Anabolic agent; Antiresorptive agent; Combination therapy; Parathyroid hormone; Sequential therapy

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; PARATHYROID HORMONE[1-34]; PLACEBO;

BONE DENSITY; BONE TURNOVER; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENCY; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; TREATMENT OUTCOME;

ANABOLIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FRACTURES, SPONTANEOUS; HUMANS; OSTEOGENESIS; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 23044507489     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000166383.73153.cf     Document Type: Review

References (46)

1. Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 2004; 164:1525-1530.
2. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther 2004; 26:841-854.
3. Dobnig H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother 2004; 5:1153-1162.
4. Madore GR, Sherman PJ, Lane JM. Parathyroid hormone. J Am Acad Orthop Surg 2004; 12:67-71.
5. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004; 89:3332-3336. This study demonstrated the time course for the changes in bone formation markers followed by serum markers of osteoclast maturation (RANKL and IL-6) with daily PTH administration for 1 year and 1 year of follow-up in postmenopausal women with glucocorticoid-induced osteoporosis.
6. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18:1932-1941.
7. Sato M, Westmore M, Ma YL, et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 2004; 19:623-629.
8. Lotinun S, Evans GL, Bronk JT, et al. Continuous parathyroid hormone induces cortical porosity in the rat: effects on bone turnover and mechanical properties. J Bone Miner Res 2004; 19:1165-1171.
9. Horwitz M, Stewart A, Greenspan SL. Sequential parathyroid hormone/alendronate therapy for osteoporosis-robbing Peter to pay Paul? J Clin Endocrinol Metab 2000; 85:2127-2128.
10. Frost HM. Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Relat Res 1979; Sep:227-244.
11. Reeve J, Podbesek RD, Price TR, et al. Studies for a 'short-cycle' ADFR regime using parathyroid peptide hPTH 1-34 in idiopathic osteoporosis and in a dog model. In: Copenhagen International Symposium on Osteoporosis; 1984; Copenhagen, Denmark; 1984.
12. Hesch RD, Heck J, Delling G, et al. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover. Klin Wochenschr 1988; 66:976-984.
13. Iwaniec UT, Samnegard E, Cullen DM, et al. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone 2001; 29:352-360.
14. Ejersted C, Oxlund H, Andreassen TT. Bisphosphonate maintains parathyroid hormone (1-34)-induced cortical bone mass and mechanical strength in old rats. Calcif Tissue Int 1998; 62:316-322.
15. Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 2002; 143:3230-3242.
16. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349:1216-1226.
17. Neer R, Hayes A, Wyland J, et al. Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2004; 19(Suppl 1):S98.
18. Recker RR, Bare SP, Miller MA, et al. Treatment of osteoporotic women with parathyroid hormone 1-84 for 18 months improves cancellous bone formation and structure: a bone biopsy study. J Bone Miner Res 2004; 19:S97.
19. Cosman F, Nieves JW, Luckey MM, et al. Daily versus cyclic PTH combined with alendronate versus alendronate alone for the treatment of osteoporosis. J Bone Miner Res 2003; 18(Suppl 2):S32.
20. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550-555.
21. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001; 16:925-931.
22. Hesch RD, Busch U, Prokop M, et al. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989; 44:176-180.
23. Reeve J, Bradbeer JN, Arlot M, et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1991; 1:162-170.
24. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980; 280:1340-1344.
25. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349:1207-1215.
26. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997; 82:620-628.
27. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85:720-726.
28. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-137.
29. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11:1043-1051.
30. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142:5050-5055.
31. Shevde NK, Bendixen AC, Dienger KM, et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000; 97:7829-7834.
32. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12.
33. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140:4367-4370.
34. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100.
35. Klein BY, Ben-Bassat H, Breuer E, et al. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem 1998; 68:186-194.
36. Giuliani N, Pedrazzoni M, Negri G, et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998; 22:455-461.
37. Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000; 60:6001-6007.
38. Giuliani N, Pedrazzoni M, Passeri G, et al. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998; 27:38-41.
39. Miller PD. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Engl J Med 2004; 350:189-192; author reply 189-192.
40. Recker R, Lappe J, Davies KM, et al. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004; 19:1628-1633.
41. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004; 15:992-997.
42. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2004; Aug 18. [E-pub ahead of print.]
43. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000; 85:2129-2134.
44. Black DM, Rosen CJ, Palermo L, et al. The effect of 1 year of alendronate following 1 year of PTH 1-84: second year results from the PTH and alendronate (PaTH) trial. J Bone Miner Res 2004; 19(Suppl 1):S26.
45. Zanchetta JR, Rubio L, Mango A, et al. Changes in BMD at different skeletal sites after discontinuation of treatment with rhPTH (1-34) in postmenopausal osteoporotic women. J Bone Miner Res 2003; 18(Suppl 2):S32.
46. Kurland ES, Cosman F, Rosen CJ, et al. Parathyroid hormone (PTH 1-34) as a treatment for idiopathic osteoporosis in men: changes in bone mineral density, bone markers, and optimal duration of therapy. J Bone Miner Res 2000; 15(Suppl 1):S230.